Cardiogeni Celebrates Successful Listing on Aquis Growth Market
Deal News | Feb 03, 2025 | Reynolds Porter Chamberlain (RPC)
International law firm Reynolds Porter Chamberlain (RPC) has provided legal advisory services to Cardiogeni PLC, a UK-based clinical-stage biotechnology company, facilitating its successful listing on the Aquis Stock Exchange's Access segment. This admission marks a significant milestone for Cardiogeni as it seeks to leverage new investment opportunities through the capital markets. The strategic move underlines Cardiogeni's ambitions in the biotechnology field, aiming to advance its clinical-stage innovations. The expertise of RPC in guiding Cardiogeni through this complex process underscores the pivotal role of experienced legal advisory in navigating market listings on alternative exchanges.
Sectors
- Biotechnology
- Legal Services
- Financial Markets
Geography
- United Kingdom – Cardiogeni PLC is a UK-based biotechnology company. The Aquis Stock Exchange, where the listing took place, also operates within the UK.
Industry
- Biotechnology – The article is about Cardiogeni PLC, a biotechnology company engaged in clinical-stage developments, listing on a stock exchange.
- Legal Services – RPC, a law firm, was involved in advising Cardiogeni PLC on its market listing, which is a legal and compliance-related activity.
- Financial Markets – The listing on the Aquis Stock Exchange involves navigating financial markets for public trading of Cardiogeni PLC's shares.
Financials
- – No specific financial information such as deal price or company valuation is mentioned in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Cardiogeni PLC | Target Company | Company | A UK-based clinical-stage biotechnology company listed on the Aquis Growth Market. |
| Reynolds Porter Chamberlain (RPC) | Legal Advisor | Company | An international law firm that advised Cardiogeni PLC on its market listing. |